This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Health care stocks edged up on analysts' actions and regulatory approvals Tuesday, though disappointing earnings tempered gains.

After PDL BioPharma (PDLI - Get Report) said Monday that CEO Mark McDade would leave by the end of the year, despite being cleared in an internal investigation, First Albany upgraded the stock to buy from neutral. Shares continued to climb Tuesday, gaining 72 cents, or 3.1%, to $23.64.

First Albany also downgraded Adams Respiratory Therapeutics (ARXT) to buy from strong buy, and upped its price target for Myriad Genetics (MYGN - Get Report) to $49 from $44.

Adams reported a loss of $1 million, or 3 cents a share, compared to a profit of $6.4 million, or 17 cents a share, in the year-ago period. It surpassed expectations of analysts polled by Thomson Financial, who predicted a loss of 4 cents per share. However, it guided below the consensus estimate for 2008. The company sees earnings of between $1.55 and $1.75 a share, vs. analysts' expectation of $1.84 a share. Shares gave up $4.62 or 11.4%, to $36.10.

Myriad lost $7.8 million, or 18 cents a share, compared with a loss of $11.4 million, or 29 cents a share, in the year-ago period. Revenue rose to $45.5 million from $32 million. Analysts expected a loss of 19 cents a share on revenue of $42.9 million. But shares still edged down $1.09, or 2.5%, to $42.03.

Adams and Myriad are both components of the Nasdaq Biotechnology index, which was up 1.88, or 0.22%, to 799.96.

DJO (DJO) gained 1% after saying it received FDA approval for new features for its existing bone growth stimulation devices. The new features will make the products easier to use. The stock was up 49 cents to $47.91.

St. Jude (STJ - Get Report) said it received approval from Japan's Ministry of Health, Labor and Welfare, for its Angio-Seal STS Plus Vascular Closure device. The company also received reimbursement approval for the device in Japan. Shares were up 7 cents to $43.33.

Genta (GNTA) gained 6.3%, after it said it enrolled its first patients in AGENDA, its phase III trial for Genasense Injection treatment for advanced melanoma. The company plans to accrue 300 patients worldwide in about 18 months. Shares rose 5 cents to 85 cents.

Elsewhere, Encysive Pharmaceuticals (ENCY) said it would sell 7.7 million shares to institutional investors for $1.95 a share. The offering is expected to raise $15 million in proceeds, before fees and expenses. The company also will issue five-year warrants to purchase 7.7 million shares at the same exercise price. The company will use the $15 million for working capital and general corporate purposes, including commercialization of hypertension drug Thelin in Europe, Canada and Australia.

The company expects to close the offering or before Friday. Shares slipped 14 cents, or 7.1%, to $1.84.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MYGN $36.01 -1.80%
PDLI $3.59 -1.60%
STJ $75.84 -0.60%
AAPL $93.92 0.29%
FB $117.83 -0.62%


Chart of I:DJI
DOW 17,698.80 -192.36 -1.08%
S&P 500 2,058.67 -22.76 -1.09%
NASDAQ 4,759.78 -57.8140 -1.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs